Update in Prescribing and therapeutics: NSAID’s in Emergency Medicine.

Slides:



Advertisements
Similar presentations
WHAT ABOUT THE IMP? IMP HANDLING FOR THE TRIAL SITE PHARMACY.
Advertisements

Quiz About Medication Errors Medication Safety Thermometer Event Thursday 23 rd January 2014.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
NSAIDs and GI and Renal Complications Lessons from Tennessee Medicaid population studies (and selected others)
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen.
Getting the most out of your Arthritis medicines & your Pharmacist Kathy Maxwell Community Pharmacist Hillpark Care Chemist, Manurewa.
Australasian Society of Clinical Immunology and Allergy Adverse Reactions to NSAIDs David Henry Faculty of Medicine and Health Sciences The University.
Canadian Cardiovascular Society Antiplatelet Guidelines
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
Clinical Issues in the Management of Non Communicable Diseases Dr Gyaneshwar Rao Colonial War Memorial Hospital Suva.
Presenter Disclosure Information
An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Who are they? Archie Cochrane The Cochrane Collaboration Formed in ,000+ people in 80+ countries 50 Collaborative Review Groups 12 Centres, Fields,
An epidemiologic perspective on etoricoxib David J. Graham, MD, MPH Office of Surveillance and Epidemiology April 12, 2007.
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
CRITICAL APPRAISAL OF ARTICLE ON HARM. Among patients with acute rheumatic fever, will administration of non steroidal anti- inflammatory drugs have adverse.
Update of TARGET ( T reatment a nd R elief of G astroint e s t inal disorder) DR NORITA YASMIN MORNING READ 19/9/13 1.
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:
VIOXX ™ Gastrointestinal Outcome Research (VIGOR) Arthritis Advisory Committee Meeting February 8, 2001 Lourdes Villalba, M.D. DAAODP, CDER, FDA.
Comparison of two cardiovascular risk assessment tools to determine appropriate use of aspirin as primary prevention for patients with type 2 diabetes.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
NDAs /772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products.
CV Update – Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet – 27/01/09 Dr Ameet Bakhai, FRCP – Cardiologist, Clinical Trials, Health.
PCI for STEMI Ari de la Hera, M.D..
NSAIDs.
What about VIOXX?. Adenomatous Polyp Prevention on Vioxx (APPROVe) Vioxx (rofecoxib) versus Placebo Basic Clinical Trial Objective: Assess whether Vioxx.
Diabetes: Beyond Sugar. CHAOS C - Coronary artery disease H - Hyper-tension, -glycaemia, -insulinaemia A - Atherosclerosis O - Obesity S - Stroke.
Hot Topic Presentation Lars Halford, GP ST3 March 2010
East & South East England Specialist Pharmacy Services East of England, London, South Central & South East Coast NSAIDS – Efficacy and Safety Expert speaker.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
NHS Specialist Pharmacy Service Medicine Use Reviews NSAIDs NHS Specialist Pharmacy Service Medicines Use & Safety.
Internal Medicine Workshop Series Laos September /October 2009.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
Date of download: 6/28/2016 From: Effects of Blood Pressure Reduction in Mild Hypertension: A Systematic Review and Meta-analysis Ann Intern Med. 2015;162(3):
NHS Specialist Pharmacy Service NSAIDS – efficacy and safety Expert speaker Slide set Key content from the NPC NSAIDS QIPP slides is gratefully acknowledged.
Clinical Knowledge Summaries CKS Analgesia – mild to moderate pain Prescribing analgesics for mild to moderate pain in adults and children. Educational.
Choosing Wisely Pharmacy’s Role and Recommendations Mary Wong
Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.
Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
Appropriate Use of NSAIDs
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Fig. 1. Age-dependent distribution of AKI risk factors
Clinical Reader in Clinical Pharmacology
The Anglo Scandinavian Cardiac Outcomes Trial
Selection of NSAIDs for Osteoarthritis
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Laurent Macle, MD, John Cairns, MD, Kori.
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.
Volume 120, Issue 3, Pages (February 2001)
Drug used within 3 months of index date Adjusted odds ratio* p
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Risk of Upper Gastrointestinal Complications Among Users of Traditional NSAIDs and COXIBs in the General Population  Luis A. García Rodríguez, Laura Barreales.
OTC NSAID Use in Patients With OA and CV Disease
Volume 387, Issue 10033, Pages (May 2016)
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials 
Volume 153, Issue 3, Pages (September 2017)
Coxibs—Beyond the GI Tract
Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised,
Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2  Robert N. Foley, Charles A. Herzog, Allan.
Update on OTC Pain Relievers for Osteoarthritis
Treating Osteoarthritis
Volume 382, Issue 9894, Pages (August 2013)
Volume 147, Issue 4, Pages (October 2014)
Hugh Taggart, MD, Michael A
Internal Medicine Workshop Series Laos September /October 2009
Erratum Canadian Journal of Cardiology
Non opioids pain management
Presentation transcript:

Update in Prescribing and therapeutics: NSAID’s in Emergency Medicine

Relative risk comparison – GI and vascular side effects The Lancet Aug 2013, 382:9894 pp769 – 779

Recommendations 1. ALL NSAIDS should be used at the lowest dose possible for the shortest time period possible 2. Ibuprofen & Naproxen are considered to have the safest cardiovascular risk profile of all the NSAIDS 3. Patients with Ischaemic heart disease, Peripheral artery disease, cerebrovascular disease and congestive cardiac failure should NOT be prescribed diclofenac. 4. Careful consideration should be given to initiating Diclofenac in those with significant risk factors for cardiovascular disease;( e.g. smoking, diabetes mellitus, hypertension and hyperlipidaemia.)

Recommendations Consideration should be given to PPI prescribing with NSAID’s in those at high risk of GI complications - >65yrs, PMH of ulcers and other medications with GI risks Concomitant prescribing with ACE inhibitors should be avoided Concomitant prescribing with Aspirin should be avoided

References P, Henry D (2011) Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 8(9): e doi: /journal.pmed Vascular and Upper Gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials by the Coxib and traditional NSAID trialists collaboration The Lancet Aug 2013, 382:9894 pp769 – MHRA drug safety update on diclofenac accessed 30 th May Recommendations relating to PPI prescribing MHRA drug safety update relating to renal risk and ACE inhibitors